Research
Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior weight loss compared to semaglutide and placebo in patients with obesity.
Tirzepatide (5-15 mg weekly) is a potent option for obesity, achieving up to 21% weight loss in trials. It is a dual GIP/GLP-1 agonist. Consider it if semaglutide is insufficient or not tolerated, provided cost and access allow.
StrongSupportsHIGH confidence
In the SURMOUNT-1 trial... tirzepatide was associated with a decrease in body weight of 15 %, 19.5 %, and 20.9 % at a dose of 5 mg, 10 mg, and 15 mg, respectively, from baseline to week 72 compared to placebo
Why this rating
Based on Phase III SURMOUNT-1 trial data cited in the review.
Source
Onboarding obesity management in cardiovascular care: A cardiologist's guide to latest advances
François Schiele et al. · American Journal of Preventive Cardiology · 2025
narrative_reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →